| 1 |
Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease[J]. Am J Kidney Dis,2006,28(1):53-61.
|
| 2 |
Teruel-Briones JL, Fernández-Lucas M, Rivera-Gorrin M, et al.Progression of residual renal function with an increase in dialysis:haemodialysis versus peritoneal dialysis [J]. Nefrologia, 2013, 33(5):640-649.
|
| 3 |
Verdalles U, Abad S, Vega A, et al. Factors related to the absence of anemia in hemodialysis patients[J]. Blood Purif,2011,32(1):69-74.
|
| 4 |
Port FK, Pisoni RL, Bommer J, et al. Improving outcomes for dialysis patients in the international dialysis outcomes and practice patterns study [J]. Clin J Am Soc Nephrol, 2006, 1(2): 246-255.
|
| 5 |
Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study(DOPPS) [J]. Nephrol Dial Transplant,2004,19(1):121-132.
|
| 6 |
KDIGO Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease [J]. Kidney Inter Suppl,2012,2(4):279-335.
|
| 7 |
肾性贫血诊断与治疗中国专家共识[J]. 中华肾脏病杂志,2013,29(5):389-392.
|
| 8 |
Locatelli F, Covic A, Eckardt K-U, et al, Anaemia management in patients with chronic kidney disease:a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)[J]. Nephrol Dial Transplant,2009,24(2):348-354.
|
| 9 |
Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease [J]. Iran J Kidney Dis,2013,7(1):9-22.
|
| 10 |
US Renal Data System. Annual data report [DB/OL]. 2012:152-164. http: / /www. usrds. org/ atlas12.aspx.
|
| 11 |
Garrancho JM, Kirchgessner J, Arranz M, et al. Haemoglobin level and vascular access survival in haemodialysis patients [J]. Nephrol Dial Transplant,2005,20(11):2453-2457.
|
| 12 |
Pharommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis [J]. Lancet 2007,369(9559):381-388.
|
| 13 |
Koulouridis I, Alfayez M, Thomas A, et al. Dose of erythropoiesisstimulating agents and adverse outcomes in CKD: a metaregression analysis [J]. Am J Kidney Dis,2013,61(1):44-56.
|
| 14 |
Yang W,Israni RK,Brunelli SM,et al. Hemoglobin variability and mortality in ESRD [J]. J Am Soc Nephrol, 2007,18(12): 3164-3170.
|
| 15 |
Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations [J]. Clin J Am Soc Nephrol, 2006, 1(6): 1205-1210.
|
| 16 |
Gaweda AE, Aronoff GR, Jacobs AA, et al. Individualized anemia management reduces hemoglobin variability in hemodialysis patients[J]. J Am Soc Nephrol,2014,25(1):159-66.
|
| 17 |
Lau JH, Gangji AS, Rabbat CG, et al. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial [J]. Nephrol Dial Transplant,2010,25(12):4002-4009.
|
| 18 |
Servilla KS, Singh AK, Hunt WC, et al. Anemia mananegement and association of race with mortality and hospitalization in a large not-for -profit dialysis organization. Am J Kidney Dis, 2009, 54(3):498-510.
|
| 19 |
Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients [J]. Nephrol Dial Transplant, 2010, 25(11):3701-3706.
|
| 20 |
Kshirsagar AV, Freburger JK, Ellis AR, et al. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients [J]. Am J Med, 2013, 126(6): 5411-5414.
|
| 21 |
Rottembourg J, Sonigo Y, Dansaert A, et al. Intravenous iron during predialysis period improves anemia management and cardiovascular parameters in incident hemodialysis patients [J].Nephrol Ther,2013,9(7):486-493.
|
| 22 |
Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis,2013,61(6):992-1000.
|